EP1901722A4 - Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds - Google Patents

Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Info

Publication number
EP1901722A4
EP1901722A4 EP06773467A EP06773467A EP1901722A4 EP 1901722 A4 EP1901722 A4 EP 1901722A4 EP 06773467 A EP06773467 A EP 06773467A EP 06773467 A EP06773467 A EP 06773467A EP 1901722 A4 EP1901722 A4 EP 1901722A4
Authority
EP
European Patent Office
Prior art keywords
nanoparticulate
aryl
controlled release
heterocyclic compounds
release compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06773467A
Other languages
German (de)
French (fr)
Other versions
EP1901722A1 (en
Inventor
John Devane
Paul Stark
Niall Fanning
Gurvinder Rekhi
Scott Jenkins
Gary Liversidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP1901722A1 publication Critical patent/EP1901722A1/en
Publication of EP1901722A4 publication Critical patent/EP1901722A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP06773467A 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds Withdrawn EP1901722A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
PCT/US2006/023695 WO2007027273A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Publications (2)

Publication Number Publication Date
EP1901722A1 EP1901722A1 (en) 2008-03-26
EP1901722A4 true EP1901722A4 (en) 2011-06-15

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06773467A Withdrawn EP1901722A4 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Country Status (12)

Country Link
EP (1) EP1901722A4 (en)
KR (1) KR20080024206A (en)
CN (1) CN101879140A (en)
AU (1) AU2006285349A1 (en)
BR (1) BRPI0612297A2 (en)
CA (1) CA2613474A1 (en)
EA (1) EA200800092A1 (en)
HK (1) HK1117060A1 (en)
IL (1) IL188093A0 (en)
NO (1) NO20076628L (en)
SG (1) SG162811A1 (en)
WO (1) WO2007027273A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909818A2 (en) * 2008-03-07 2015-10-06 Pfizer methods, dosage forms and kit for administering ziprasidone without food
DE102008045854A1 (en) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Particles of ziprasidone and a disintegrant containing pharmaceutical composition
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
MX2016007786A (en) 2013-12-16 2017-03-03 Massachusetts Inst Technology Fortified micronutrient salt formulations.
WO2015095230A1 (en) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
MA41611A (en) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc MILLI-CAPSULE PREPARATIONS CONTAINING FREE POLYINSATURATED FATTY ACIDS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
EP0965343A2 (en) * 1998-06-15 1999-12-22 Pfizer Products Inc. Ziprasidone formulations
WO2000072847A1 (en) * 1999-05-27 2000-12-07 Pfizer Products Inc. Ziprasidone suspension
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2006109183A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
JP4613275B2 (en) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド Multiparticulate modified release composition
PL377679A1 (en) * 2002-10-25 2006-02-06 Pfizer Products Inc. Novel injectable depot formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
EP0965343A2 (en) * 1998-06-15 1999-12-22 Pfizer Products Inc. Ziprasidone formulations
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
WO2000072847A1 (en) * 1999-05-27 2000-12-07 Pfizer Products Inc. Ziprasidone suspension
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2006109183A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007027273A1 *

Also Published As

Publication number Publication date
EA200800092A1 (en) 2008-06-30
CN101879140A (en) 2010-11-10
CA2613474A1 (en) 2007-03-08
KR20080024206A (en) 2008-03-17
NO20076628L (en) 2008-03-12
BRPI0612297A2 (en) 2010-11-03
EP1901722A1 (en) 2008-03-26
WO2007027273A1 (en) 2007-03-08
AU2006285349A1 (en) 2007-03-08
SG162811A1 (en) 2010-07-29
HK1117060A1 (en) 2009-01-09
IL188093A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
IL186469A0 (en) Nanoparticulate and controlled release compositions comprising cyclosporine
IL244442B (en) Substituted acylanilide compounds and uses thereof
ZA200802602B (en) Controlled release formulation
IL184174A0 (en) Nanoparticulate and controlled release compositions comprising cephalosporin
GB0406819D0 (en) Controlled release compositions
ZA200705384B (en) Nanoparticulate candesartan formulations
IL199006A0 (en) Nanoparticulate formulations and methods for the making and use thereof
IL186609A0 (en) Nanoparticulate quinazoline derivative formulations
ZA200805646B (en) Controlled release solid preparation
PL1959925T3 (en) Controlled release microparticles
IL186778A0 (en) Stabilized composition
ZA200805706B (en) Controlled release solid preparation
GB0621160D0 (en) Compounds and uses thereof
IL187431A0 (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
HK1117060A1 (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP2124908A4 (en) Compounds and uses thereof
IL185223A0 (en) Compounds and uses thereof
EP1849481A4 (en) Composition for external use
GB0720887D0 (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
EP2120563A4 (en) Compounds and uses thereof
IL202496A0 (en) Compounds and uses thereof 849
EP1954253A4 (en) Nanoparticulate and controlled release compositions comprising cefditoren
EP2099459A4 (en) Compounds and uses thereof
EP1946780A4 (en) Controlled release solid preparation
ZA200710715B (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117060

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20110513

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101ALI20110509BHEP

Ipc: A61K 9/64 20060101AFI20070518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111213

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117060

Country of ref document: HK